卡培他滨联合奥沙利铂治疗进展期胃癌的临床观察  

Xeloda Combined with Oxaliplatin Regiment in the Treatment of Patients with Advanced Gastric Carcinoma

作　　者：闫红艳[1] 李莉[1] 

机构地区：[1]辽宁省丹东市中心医院肿瘤科,辽宁丹东118002

出　　处：《中国现代医生》2009年第8期32-33,共2页China Modern Doctor

摘　　要：目的研究卡培他滨联合奥沙利铂治疗进展期胃癌的疗效及不良反应。方法给予进展期胃癌患者XELOX方案化疗,Xeloda1000mg(/m2·次),每日2次,d1～d14;OXA130mg/m2,d1,静滴3～4h。21d为一个周期,2周期化疗结束后评价疗效。结果25例中CR1例,PR12例,SD6例,PD6例,RR为52%,中位TTP6.2个月,中位MST12.5个月,临床获益率76%。主要毒性反应为末梢神经毒性,其次为骨髓抑制、消化道反应、手足综合征,治疗中没有发生治疗相关性死亡,患者耐受性较好。结论卡培他滨联合奥沙利铂方案治疗晚期胃癌疗效肯定,毒性反应轻,并可以明显改善患者生存质量,延长患者生存期,值得临床进一步推广。Objective To observe the efficacy and the adverse effects of Xeloda combined with Oxaliplatin for the treatment of patients with advanced gastric carcinoma. Methods 25 patients with advanced gastric carcinoma were treated by Xeloda combined with Oxaliplatin regiment. Xeloda 1000mg/m^2,pro.by two times,d1-d14; Oxaliplatin 130mg/m^2,iv.for 3-4 hours,d1; q3w. The efficacy was evaluated after 2 cycles. Results Among 25 patients with advanced gastric carcinoma,there were 13（52%）objective response,including 1 complete responses and 12 partial responses. The median time to progression was 6.2 months. The median survival period was 11.5 months. The clinical benefit response rate was 76%. Neurotoxicity,myelosuppression and alimentary tract reactions were main toxicities caused by chemotherapy. There were no death caused by chemotherapy. Patients were well tolerated. Conclusion There were obvious clinical efficacies and less adverse effects in the treatment of patients with advanced gastric carcinoma while Xeloda combined with Oxaliplatin were administered. Further study should be carried out.

关 键 词：胃癌 卡培他滨 奥沙利铂 

分 类 号：R735.2[医药卫生—肿瘤]